Exelixis Inc.

24.51+0.7700+3.24%Vol 1.78M1Y Perf 3.84%
Apr 20th, 2021 16:00 DELAYED
BID24.07 ASK24.50
Open23.58 Previous Close23.74
Pre-Market- After-Market24.38
 - -  -0.13 -0.53%
Target Price
31.33 
Analyst Rating
Moderate Buy 1.58
Potential %
27.83 
Finscreener Ranking
★★★★★     60.92
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.34
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     78.16
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap7.67B 
Earnings Rating
Neutral
Price Range Ratio 52W %
65.80 
Earnings Date
4th May 2021

Today's Price Range

23.5224.53

52W Range

18.1827.80

5 Year PE Ratio Range

-49.0065.70

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.91%
1 Month
4.74%
3 Months
14.96%
6 Months
12.48%
1 Year
3.84%
3 Years
17.44%
5 Years
442.26%
10 Years
108.06%

TickerPriceChg.Chg.%
EXEL24.510.77003.24
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Earnings HistoryEstimateReportedSurprise %
Q04 20200.030.09200.00
Q03 2020-0.05-0.10-100.00
Q02 20200.120.2175.00
Q01 20200.130.1515.38
Q04 20190.150.2246.67
Q03 20190.200.3155.00
Q02 20190.230.258.70
Q01 20190.210.2414.29
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.04-33.33Negative
6/2021 QR0.07-22.22Negative
12/2021 FY0.37-28.85Negative
12/2022 FY0.97-14.16Negative
Next Report Date4th May 2021
Estimated EPS Next Report0.04
Estimates Count4
EPS Growth Next 5 Years %47.40
Volume Overview
Volume1.78M
Shares Outstanding313.10M
Trades Count15.50K
Dollar Volume33.35M
Avg. Volume2.13M
Avg. Weekly Volume1.42M
Avg. Monthly Volume1.60M
Avg. Quarterly Volume1.92M

Exelixis Inc. (NASDAQ: EXEL) stock closed at 24.51 per share at the end of the most recent trading day (a 3.24% change compared to the prior day closing price) with a volume of 1.79M shares and market capitalization of 7.67B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 773 people. Exelixis Inc. CEO is Michael M. Morrissey.

The one-year performance of Exelixis Inc. stock is 3.84%, while year-to-date (YTD) performance is 22.12%. EXEL stock has a five-year performance of 442.26%. Its 52-week range is between 18.18 and 27.8, which gives EXEL stock a 52-week price range ratio of 65.80%

Exelixis Inc. currently has a PE ratio of 67.40, a price-to-book (PB) ratio of 3.93, a price-to-sale (PS) ratio of 9.77, a price to cashflow ratio of 35.90, a PEG ratio of 2.32, a ROA of 5.34%, a ROC of 7.52% and a ROE of 6.02%. The company’s profit margin is 7.87%, its EBITDA margin is 12.10%, and its revenue ttm is $760.62 Million , which makes it $2.43 revenue per share.

Of the last four earnings reports from Exelixis Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.04 for the next earnings report. Exelixis Inc.’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for Exelixis Inc. is Moderate Buy (1.58), with a target price of $31.33, which is +27.83% compared to the current price. The earnings rating for Exelixis Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Exelixis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Exelixis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.37, ATR14 : 0.92, CCI20 : 87.93, Chaikin Money Flow : -0.06, MACD : 0.37, Money Flow Index : 72.35, ROC : 5.09, RSI : 54.70, STOCH (14,3) : 66.86, STOCH RSI : 0.60, UO : 48.26, Williams %R : -33.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Exelixis Inc. in the last 12-months were: Alan M. Garber (Option Excercise at a value of $135 200), Alan M. Garber (Sold 112 222 shares of value $2 707 661 ), Carl B. Feldbaum (Option Excercise at a value of $337 195), Carl B. Feldbaum (Sold 83 092 shares of value $2 017 762 ), Charles Cohen (Option Excercise at a value of $806 805), Charles Cohen (Sold 40 000 shares of value $907 600 ), Christopher J. Senner (Option Excercise at a value of $585 600), Christopher J. Senner (Sold 160 000 shares of value $4 080 786 ), George A. Scangos (Option Excercise at a value of $527 225), George A. Scangos (Sold 400 000 shares of value $10 379 354 ), George H. Poste (Option Excercise at a value of $829 666), George H. Poste (Sold 60 000 shares of value $1 536 600 ), Gisela M. Schwab (Option Excercise at a value of $510 000), Gisela M. Schwab (Sold 300 000 shares of value $7 138 500 ), Jack L. Wyszomierski (Option Excercise at a value of $363 185), Jack L. Wyszomierski (Sold 34 000 shares of value $700 740 ), Jeffrey J. Hessekiel (Option Excercise at a value of $2 495 626), Jeffrey J. Hessekiel (Sold 163 006 shares of value $4 111 563 ), Lance Willsey (Option Excercise at a value of $1 205 346), Lance Willsey (Sold 180 000 shares of value $4 305 536 ), Michael M. Morrissey (Option Excercise at a value of $6 664 183), Patrick J. Haley (Option Excercise at a value of $119 478), Patrick J. Haley (Sold 111 883 shares of value $2 696 090 ), Peter Lamb (Option Excercise at a value of $860 760), Peter Lamb (Sold 310 000 shares of value $6 770 800 ), Stelios Papadopoulos (Option Excercise at a value of $929 204), Stelios Papadopoulos (Sold 45 000 shares of value $1 162 800 ), Vincent T. Marchesi (Option Excercise at a value of $973 223), Vincent T. Marchesi (Sold 204 101 shares of value $4 826 396 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (66.67 %)
8 (66.67 %)
8 (72.73 %)
Moderate Buy
1 (8.33 %)
1 (8.33 %)
0 (0.00 %)
Hold
3 (25.00 %)
3 (25.00 %)
3 (27.27 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.58
Moderate Buy
1.58
Moderate Buy
1.55

Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule cabozantinib is indicated for the treatment of patients with metastatic medullary thyroid cancer (as Cometriq) and advanced renal cell carcinoma, or kidney cancer, and hepatocellular carcinoma, or liver cancer (as Cabometyx). Exelixis and partner Roche have also brought Cotellic to market for the treatment of melanoma.

CEO: Michael M. Morrissey

Telephone: +1 650 837-7000

Address: 1851 Harbor Bay Parkway, Alameda 94502, CA, US

Number of employees: 773

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

55%45%

Bearish Bullish

57%43%

News

Stocktwits